The Latest Headlines at American Banking and Market News
-inc-logo.png&w=240&h=220&zc=2){kind=logo}
Duke Energy (NYSE:DUK) Price Target Increased to $100.00 by Analysts at Barclays
Duke Energy (NYSE:DUK – Free Report) had its price objective hoisted by Barclays from $99.00 to $100.00 in a research note released on Monday morning, Benzinga reports. Barclays currently has an overweight rating on the utilities... More of this article »
Ramaco Resources (NASDAQ:METC) Given New $24.00 Price Target at B. Riley
Ramaco Resources (NASDAQ:METC – Free Report) had its price objective reduced by B. Riley from $25.00 to $24.00 in a research note issued to investors on Monday morning, Benzinga reports. They currently have a buy rating on the... More of this article »
Entergy (NYSE:ETR) Given New $107.00 Price Target at Barclays
Entergy (NYSE:ETR – Free Report) had its target price cut by Barclays from $108.00 to $107.00 in a research report report published on Monday morning, Benzinga reports. They currently have an equal weight rating on the utilities... More of this article »
American Tower (NYSE:AMT) Given New $196.00 Price Target at Morgan Stanley
American Tower (NYSE:AMT – Free Report) had its target price upped by Morgan Stanley from $183.00 to $196.00 in a report issued on Monday morning, Benzinga reports. Morgan Stanley currently has an equal weight rating on the real... More of this article »
Natera (NASDAQ:NTRA) Given New $100.00 Price Target at The Goldman Sachs Group
Natera (NASDAQ:NTRA – Free Report) had its price objective upped by The Goldman Sachs Group from $90.00 to $100.00 in a report published on Monday morning, Benzinga reports. The brokerage currently has a buy rating on the medical... More of this article »
AON (NYSE:AON) Given New $327.00 Price Target at Morgan Stanley
AON (NYSE:AON – Free Report) had its price target increased by Morgan Stanley from $325.00 to $327.00 in a research report released on Monday, Benzinga reports. They currently have an equal weight rating on the financial services... More of this article »
Neogen (NASDAQ:NEOG) Price Target Lowered to $17.00 at Piper Sandler
Neogen (NASDAQ:NEOG – Free Report) had its price target trimmed by Piper Sandler from $19.00 to $17.00 in a research report report published on Monday morning, Benzinga reports. The brokerage currently has a neutral rating on... More of this article »
Antero Resources (NYSE:AR) Price Target Raised to $27.00 at Morgan Stanley
Antero Resources (NYSE:AR – Free Report) had its target price raised by Morgan Stanley from $26.00 to $27.00 in a report published on Monday morning, Benzinga reports. Morgan Stanley currently has an equal weight rating on the... More of this article »
Azul (NYSE:AZUL) Receives Outperform Rating from Raymond James
Raymond James reiterated their outperform rating on shares of Azul (NYSE:AZUL – Free Report) in a report released on Monday morning, Benzinga reports. Raymond James currently has a $12.00 price objective on the stock, down from... More of this article »
American International Group (NYSE:AIG) Price Target Increased to $79.00 by Analysts at Morgan Stanley
American International Group (NYSE:AIG – Free Report) had its price objective increased by Morgan Stanley from $72.00 to $79.00 in a research report report published on Monday, Benzinga reports. The brokerage currently has an... More of this article »
AAR (NYSE:AIR) Price Target Raised to $83.00 at Benchmark
AAR (NYSE:AIR – Free Report) had its target price raised by Benchmark from $65.00 to $83.00 in a research report released on Monday morning, Benzinga reports. The firm currently has a buy rating on the aerospace company’s... More of this article »
American Vanguard (NYSE:AVD) Price Target Increased to $20.00 by Analysts at Loop Capital
American Vanguard (NYSE:AVD – Free Report) had its price objective upped by Loop Capital from $19.00 to $20.00 in a research report sent to investors on Monday, Benzinga reports. The brokerage currently has a buy rating on the... More of this article »
OncoCyte (NASDAQ:OCX) Given Speculative Buy Rating at Benchmark
Benchmark reissued their speculative buy rating on shares of OncoCyte (NASDAQ:OCX – Free Report) in a research note published on Monday, Benzinga reports. The brokerage currently has a $5.00 price objective on the stock. Separately,... More of this article »